Cargando…

A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab

SIMPLE SUMMARY: Pembrolizumab, a monoclonal antibody targeting programmed cell death 1, improves the survival of patients with advanced melanoma. This study aimed to investigate the association of baseline clinical characteristics, laboratory and imaging variables, and gene expression profiling scor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Awada, Gil, Jansen, Yanina, Schwarze, Julia Katharina, Tijtgat, Jens, Hellinckx, Lennert, Gondry, Odrade, Vermeulen, Sim, Warren, Sarah, Schats, Kelly, van Dam, Pieter-Jan, Kockx, Mark, Keyaerts, Marleen, Everaert, Hendrik, Seremet, Teofila, Rogiers, Anne, Neyns, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825041/ https://www.ncbi.nlm.nih.gov/pubmed/33418936 http://dx.doi.org/10.3390/cancers13020168

Ejemplares similares

Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
por: Vermeulen, Sim, et al.
Publicado: (2021)

Pembrolizumab for the treatment of uveal melanoma: A case series
por: Jansen, Yanina Jeanne Leona, et al.
Publicado: (2020)

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
por: Seremet, Teofila, et al.
Publicado: (2019)

Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases
por: Jansen, Yanina J L, et al.
Publicado: (2019)

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial
por: Schwarze, Julia Katharina, et al.
Publicado: (2022)

Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse
por: Jansen, Yanina J. L., et al.
Publicado: (2021)

A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS(Q61R/K/L) Mutant Melanoma (TraMel-WT)
por: Awada, Gil, et al.
Publicado: (2021)

The Prognostic Value of CD206 in Solid Malignancies: A Systematic Review and Meta-Analysis
por: Debacker, Jens M., et al.
Publicado: (2021)

A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases
por: Van Bael, Kobe, et al.
Publicado: (2015)

Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
por: Seremet, Teofila, et al.
Publicado: (2016)

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
por: de Filette, Jeroen, et al.
Publicado: (2016)

Development and Validation of a Predictive Model for Metastatic Melanoma Patients Treated with Pembrolizumab Based on Automated Analysis of Whole-Body [(18)F]FDG PET/CT Imaging and Clinical Features
por: Dirks, Ine, et al.
Publicado: (2023)

Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors
por: Rogiers, Anne, et al.
Publicado: (2019)

Intratumoral Combinatorial Administration of CD1c (BDCA-1)(+) Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial
por: Schwarze, Julia Katharina, et al.
Publicado: (2020)

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
por: Schreuer, Max, et al.
Publicado: (2016)

Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial
por: Duerinck, Johnny, et al.
Publicado: (2021)

Phase I Study of [(68)Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)
por: Gondry, Odrade, et al.
Publicado: (2023)

Intratumoral administration of CD1c (BDCA-1)(+) and CD141 (BDCA-3)(+) myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
por: Schwarze, Julia Katharina, et al.
Publicado: (2022)

Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report
por: Lambert, Ine, et al.
Publicado: (2021)

Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
por: Awada, Gil, et al.
Publicado: (2020)

Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab
por: Du Four, Stephanie, et al.
Publicado: (2018)

Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab
por: Rogiers, Anne, et al.
Publicado: (2020)

Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series
por: Tijtgat, Jens, et al.
Publicado: (2023)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
por: Tijtgat, Jens, et al.
Publicado: (2021)

Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1
por: Awada, Gil, et al.
Publicado: (2020)

Allergic contact dermatitis from a skin‐calming cream containing hydroxyphenyl propamidobenzoic acid
por: Blanchard, Gabriela, et al.
Publicado: (2022)

Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression
por: Van Berckelaer, C., et al.
Publicado: (2019)

Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports
por: Wilgenhof, Sofie, et al.
Publicado: (2012)

Allergic contact dermatitis from pantolactone and dexpanthenol in wound healing creams
por: Blanchard, Gabriela, et al.
Publicado: (2022)

(18)F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma
por: Wong, Annie, et al.
Publicado: (2020)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm
por: Lecocq, Quentin, et al.
Publicado: (2020)

Pembrolizumab for all
por: Kim, Myung S., et al.
Publicado: (2022)

First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes
por: Lang, David, et al.
Publicado: (2021)

Hysteresis in myo‐inositol utilization by Salmonella Typhimurium
por: Hellinckx, Jessica, et al.
Publicado: (2016)

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy
por: Murakami, Shuji, et al.
Publicado: (2020)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Pembrolizumab-associated sarcoidosis
por: Cotliar, Jonathan, et al.
Publicado: (2016)

Pembrolizumab-induced pneumonitis
por: Leroy, Vincent, et al.
Publicado: (2017)

Advances on broad-band wireless computing, communication and applications: proceedings of the 14th international conference on broad-band wireless computing, communication and applications (BWCCA-2019)
por: Barolli, Leonard, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4ieonavv23rrk30ua4f1ed68gk